Line Christa Amanda Sørensen’s Post

CACHE competition: Unveiling the power and limitations of AI in drug discovery The results are in from the CACHE hit-finding competition, and they offer a fascinating glimpse into the potential of AI for drug discovery. Over 2,000 compounds, 23 teams, and a tough Parkinson's target yielded a <1% hit rate. But hey, that's not a failure – this transparency around data and methods is a crucial step forward, as it paves the way for independent validation and fuels collaboration. This is exactly what we need to refine computational/AI driven driven hit-finding and unlock its true potential. What are your thoughts on the CACHE results? Hit reply and share your insights! #drugdiscovery #ai #CACHECompetition #aidrugdiscovery

This week, Parexel's Stephen Pyke and other industry experts will gather at Bloomberg's AI and Drug Development Forum in New York to explore how AI is revolutionizing the $1.6 trillion global drug development industry. 🎙 Stephen will join Bloomberg's VaNae N. Hamilton, Ph.D. for the panel "AI and the Approval/Post-Approval Process," to discuss: • AI's role in the current regulatory framework • Future possibilities for AI in drug approvals • Integration of AI in manufacturing and commercialization We're proud to be part of conversations that are shaping the future of AI in drug development. Stay tuned for more! #AI #ArtificialIntelligence #Bloomberg

AI is here – and it’s rapidly changing how we work. In healthcare and life science, there’s both excitement 🤩 and uncertainty 🤔. It is more important than ever that companies are implementing their AI effectively, while maintaining ethical standards. So how do you govern AI – and introduce it in a safe way? Gartner ® offers a comprehensive answer in their latest report: ‘Drive AI Impact and Value in Healthcare and Life Science by Establishing Strong Governance’ To unlock the report, click here 👉 https://brnw.ch/21wLVt0 #magnoliadxp #biopharma #pharma #healthcare

Building upon our earlier study on "Artificial Intelligence in Drug Discovery & Development Vol 1.0," where we provided insights into AI's role in drug discovery, its diverse applications, prominent stakeholders, and significant investments in the field, we have revisited our sector analysis to offer a refreshed perspective. This Vol 2.0 study on the role of AI in drug discovery sheds light on both the challenges and the opportunities on the horizon. The traditional path of drug development, marked by its high costs and lengthy timelines, finds a revolutionary solution in AI-driven methodologies. These cutting-edge approaches, powered by the capabilities of machine learning, streamline processes from identifying targets to optimizing leads, offering the potential to expedite the discovery pipeline and improve therapeutic effectiveness. Looking ahead, the integration of AI and drug discovery holds the promise of unparalleled advancements in healthcare. Despite hurdles like data quality and regulatory compliance, collaborative efforts and continued investment hold the key to realizing AI's full potential. By championing interdisciplinary partnerships and nurturing talent, we pave the way for groundbreaking innovations that redefine the future of medicine. #AI #DrugDiscovery #HealthcareInnovation #ArtificialIntelligence #FutureofMedicine #ScienceandTechnology #InnovateTogether 

Looking to enhance your global research strategy? 🌍 With cutting-edge labs strategically located in North America and Europe, we provide a unique advantage in delivering customized solutions powered by AI technologies for our clients: • Global expertise: Our North American and European teams bring together a wealth of insights, diverse perspectives and extensive experience, culminating in comprehensive solutions customized to your needs. • Innovation hub: Utilize our labs as innovation hubs. From advanced technologies to pioneering methodologies, we continually push the boundaries of research excellence. • Collaborative advantage: Our collective teams across continents seamlessly collaborate, fostering creativity, efficiency, and shared success with you. • Results-driven solutions: Whether it's accelerating timelines, expanding market reach, or driving cost efficiencies, our focus is on delivering tangible outcomes for you. Discover how the Hub of Biotherapeutic Intelligence can work for you: https://bit.ly/4atDeJ3 #GlobalResearch #InnovationHub #ArtificialIntelligence #AI #Antibodies #mAb #DrugDiscovery #Pharma BioStrand (a subsidiary of IPA)

An interesting report was published in Nature Reviews Drug Discovery, about the benefits of #AI in screening, one of the many places where many people are expecting some near-magical impact... A few quotes that caught my attention: "One takeaway is that classical methods can still keep up with AI-based methods." "The question is, do we need really complicated, advanced AI technologies at every stage of the process?" "It's not likely we’ll find a universally applicable solution for every target." As a community we need to embrace #AI not as a magic wand but apply the proverbial "Healthy Dose of Skepticism" and match the method to the task rather than the other way around. https://lnkd.in/gzKiKCz2

Very interesting insights from McKinsey & Company on #GenAI in #pharma. Thank you for sharing, Chris Wright. The article explores how AI is moving from hype to reality, transforming drug discovery and development. My 2 key takeaways: 1) there is a clear opportunity to apply AI into R&D processes, enhancing efficiency and innovation. One Canadian 🇨🇦 company I have been following to this effect is BenchSci 2) as AI capabilities grow, so does the potential to revolutionize treatment discovery and patient outcomes. Molecular design, optimizing clinical trials, and personalizing treatment are just a few examples of areas that are ripe for AI disruption. What other business processes can you envision AI enhancing efficiency, helping cut costs, and bringing new therapies to market faster?

Explore the potential of generative AI (Gen AI) to revolutionize drug development. Read Axendia, Inc.'s Market Research Report, "The State of Generative AI in Life Sciences: The Good, The Bad, The Ugly," and gain insights into: - Opportunities for utilizing Gen AI in drug discovery. - Potential roadblocks to overcome. Read more https://ow.ly/xqCY50So8kZ #DrugDiscovery #LifeSciences #MarketResearch #GenerativeAI #GenAI #ArtificialIntelligence #MachineLearning #RegulatoryCompliance #DataPrivacy #DigitalTransformation #PharmaceuticalIndustry #ClinicalTrials #LifeScienceAI #PharmaAI

Simon Wagschal talks about the evolving landscape of API and drug substance development and a trend towards longer synthetic routes. Read our R&D blog about a route scouting solution for these increasingly complex molecules, which combines AI-driven retrosynthetic analysis with the technical knowledge and experience of our experts. #AHealthierWorld #Innovation #PharmaceuticalManufacturing #AI #SmallMolecules https://lnkd.in/eqtJJKR2

Can advanced AI-driven models revolutionize drug discovery and prevent future pandemics? In the wake of global health crises like COVID-19, it's become crucial to rethink how we approach drug design. Our latest project leverages deep generative models integrated with explainable AI to discover new chemical compounds. By using the ZINC15 dataset and focusing on drug-target interactions, we’re not just generating molecules but understanding why and how they work. This transparency is key to accelerating the drug development pipeline. What’s the impact? By reducing the trial-and-error phase, we can save up to 30% of resources—whether it's time, cost, or manpower. This kind of efficiency could have made a significant difference in the early stages of COVID-19. In real-time, AI can analyze billions of compounds, enabling us to respond to emerging health threats faster and with more precision. As we continue developing AI solutions in generative chemistry, the potential to safeguard the future of global healthcare becomes more achievable. #GenerativeAI #DrugDiscovery #AIForHealth #ExplainableAI #HealthcareInnovation #ZINC15 #FutureOfMedicine